New combo therapy trial aims to boost stomach cancer survival
NCT ID NCT03257163
Summary
This study is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation improves outcomes for people with operable stomach cancer. It focuses on two specific types: cancers with mismatch repair deficiency or Epstein-Barr virus positivity. The treatment is given before and after surgery to try to prevent the cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University
Atlanta, Georgia, 30308, United States
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton
Hamilton, New Jersey, 08690, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
Conditions
Explore the condition pages connected to this study.